medigraphic.com
SPANISH

Salud Jalisco

ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2020, Number 2

<< Back Next >>

Sal Jal 2020; 7 (2)

Comparación del desempeño de un dispositivo basado en detección vía anticuerpos vs Quantiferon TB gold in tube para diagnóstico de tuberculosis en pacientes con diabetes mellitus

López-Romero W, Camacho-Villegas T, Segura-Cerda CA, González-Salazar F, Flores-Valdez MA
Full text How to cite this article

Language: Spanish
References: 14
Page: 103-112
PDF size: 300.78 Kb.


Key words:

No keywords

ABSTRACT

Tuberculosis (TB) leads to about 1.3 million deaths per year in the world, along with 10 million new cases per year. One of the risk factors for the development of pulmonary TB is diabetes mellitus (DM), where, in Mexico, an estimated 25% of diabetic patients simultaneously suffer from TB. Since the TB / DM comorbidity makes it difficult to treat both conditions, WHO and the International Union against Tuberculosis and Pulmonary Disease recommend examining patients with newly diagnosed TB for diabetes and considering detecting TB in diabetic patients. In previous reports, IGRAs have been found to have difficulties in diagnosing TB in diabetic populations. Based on this, in this work the sensitivity of a test developed by a Jalisco´s company to detect TB in patients with DM was evaluated and compared with the Quantiferon TB gold in tube standard. Our results show that DM reduces the sensitivity of QFT and that the test developed by a Jalisco´s company presents sensitivity values and diagnostic specificity of TB in acceptable range according to WHO criteria in people without DM.


REFERENCES

  1. Barron, M. M., Shaw, K. M., Bullard, K. M., Ali, M. K., & Magee, M. J. (2018). Diabetes is associated with increased prevalence of latent tuberculosis infection: Findings from the National Health and Nutrition Examination Survey, 2011– 2012. Diabetes research and clinical practice, 139, 366-379.

  2. Bastian, I., & Coulter, C. (2017). Position statement on interferon-γ release assays for the detection of latent tuberculosis infection.

  3. Faurholt Jepsen, Daniel & Aabye, Martine & Jensen, Andreas & Range, Nyagosya & Praygod, George & Jeremiah, Kidola & Changalucha, John & Faurholt Jepsen, Maria & Jensen, Lotte & Jensen, Signe & Krarup, Henrik & Ravn, Pernille & Friis, Henrik & Andersen, Ase. (2014). Diabetes is associated with lower tuberculosis antigen-specifi c interferon gamma release in Tanzanian tuberculosis patients and non-tuberculosis controls. Scandinavian journal of infectious diseases. 46. 10.3109/00365548.2014.885657.

  4. Jimenez Corona, M. E., Cruz Hervert, L. P., Garcia Garcia, L., Ferreyra Reyes, L., Delgado Sanchez, G., Bobadilla Del Valle, M., . . . Ponce de Leon, A. (2013). Association of diabetes and tuberculosis: impact on treatment and posttreatment outcomes. Th orax, 68(3), 214-220. doi:10.1136/ thoraxjnl-2012-201756

  5. Kumar Nathella, P., and Babu, S. (2017). Infl uence of diabetes mellitus on immunity to human tuberculosis. Immunology 152, 13-24.

  6. López Ramos, J. E., Macías Segura, N., Cuevas Cordoba, B., Araujo Garcia, Z., Bastián, Y., Castañeda Delgado, J. E., ... & Enciso Moreno, J. A. (2018). Improvement in the diagnosis of tuberculosis combining Mycobacterium tuberculosis immunodominant peptides and serum host biomarkers. Archives of medical research, 49(3), 147-153.

  7. Martinez, N., and Kornfeld, H. (2014). Diabetes and immunity to tuberculosis. Eur J Immunol 44, 617-626.

  8. Organización. M. S.(2019). “Global tuberculosis report”, (ed.) Onu.)

  9. Penuelas Urquides, K., Martinez-Rodriguez, H. G., Enciso Moreno, J. A., Molina Salinas, G. M., Silva Ramirez, B., Padilla Rivas, G. R., . . . Said Fernandez, S. (2014). Correlations between major risk factors and closely related Mycobacterium tuberculosis isolates grouped by three current enotyping procedures: a population-based study in northeast Mexico. Memorias do Instituto Oswaldo Cruz, 109(6), 814-819.

  10. Restrepo, B.I. (2016). Diabetes and Tuberculosis. Microbiol Spectr 4.

  11. Secretaría S.J. (2018). “Boletín semanal de epidemiología”, consultado en https://ssj.jalisco.gob.mx/sites/ssj.jalisco.gob.mx/ fi les/bole_51_-_2018.pdf

  12. Tulshidas S. Patil & Ashwini S. Deshpande (2018) Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017), Expert Opinion on Th erapeutic Patents, 28:8, 615-623, DOI: 10.1080/13543776.2018.1508454

  13. Viswanathan, A.A., and Gawde, N.C. (2014). Eff ect of type II diabetes mellitus on treatment outcomes of tuberculosis. Lung India 31, 244-248.

  14. Workneh, M. H., Bjune, G. A., & Yimer, S. A. (2017). Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One, 12(4), e0175925. doi:10.1371/journal.pone.0175925




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Sal Jal. 2020;7